Compass Therapeutics Stock
Compass Therapeutics is a biopharmaceutical company focused on drugging the immune system to treat human diseases.
Sign up today and learn more about Compass Therapeutics Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Compass Therapeutics Stock
We’re building Compass with a singular goal in mind: unlocking the complexity of the immune system. Our discovery and development teams work together to fully characterize and evaluate novel antibodies and rapidly generate therapeutic candidates. We are leveraging those insights to develop transformational therapies for cancer, inflammation and autoimmune diseases. We are a privately held company; our financing has been led by OrbiMed Advisors, F-Prime Capital, Cowen Healthcare Investments, Thiel Capital, Biomatics Capital, Borealis Ventures, Alexandria Real Estate Ventures and Biomed Realty Ventures.
Funding History
| May 2015 | $575K |
|---|---|
| July 2015 | $16.0M |
| September 2016 | $50.0M |
| July 2018 | $49.0M |
Management
CEO
Thomas Schuetz
Co-Founder, President/COO
Errik Anderson
Press
Wall Streets Journal - Jul, 12 2018
Compass Therapeutics Adds $49 Million to Series AEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
